Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) — Leading securities‑litigation firm Wolf Haldenstein Adler Freeman & Herz LLP is calling on purchasers or acquirers of the American Depositary Shares (ADS) of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025 (the “Class Period”) to contact the firm by the deadline of January 9, 2026 for possible appointment as lead plaintiff in a class action. The lawsuit alleges that Telix and its senior officers overstated material facts, including the progress of its prostate cancer therapeutic candidates and the quality of its supply‑chain and partner operations. Key developments cited in the complaint: On February 20, 2025, after the market closed, Telix’s earnings call for its 2024 fiscal year claimed “great progress” across its therapeutic pipeline — especially in late‑stage assets involving brain, kidney and prostate cancer programs — and touted strategic acquisitions and build‑out of global manufacturing infrastructure. On July 22, 2025, before the market opened, Telix filed a Form 6‑K disclosing that the U.S. Securities and Exchange Commission (SEC) had issued a subpoena relating to its prostate‑cancer drug disclosures. On that news, the ADSs fell as much as 16%, the largest drop in 21 months. On August 28, 2025, Telix announced publicly that the U.S. Food & Drug Administration (FDA) had issued a Complete Response Letter for its renal‑cancer drug candidate, requesting additional data. On that day, the ADSs dropped 16.1% and fell further the next day. Wolf Haldenstein underscores that it has more than 125 years of experience in securities‑fraud litigation and is offering representation to harmed investors. Investors who purchased or acquired Telix ADSs during the Class Period and suffered losses are urged to contact the firm by phone at (800) 575‑0735 or (212) 545‑4774, or via email at . #TelixPharmaceuticals #InvestorAlert #SecuritiesClassAction #LeadPlaintiffDeadline #SlimScan #GrowthStocks #CANSLIM